JP2024525791A - 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体 - Google Patents

治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体 Download PDF

Info

Publication number
JP2024525791A
JP2024525791A JP2024502013A JP2024502013A JP2024525791A JP 2024525791 A JP2024525791 A JP 2024525791A JP 2024502013 A JP2024502013 A JP 2024502013A JP 2024502013 A JP2024502013 A JP 2024502013A JP 2024525791 A JP2024525791 A JP 2024525791A
Authority
JP
Japan
Prior art keywords
formula
compound
cancer
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525791A5 (https=
Inventor
アントニオ・アルマリオ
ダニエル・デペレッティ
アメリー・ドゥメルグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2024525791A publication Critical patent/JP2024525791A/ja
Publication of JP2024525791A5 publication Critical patent/JP2024525791A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024502013A 2021-07-16 2022-07-12 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体 Pending JP2024525791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305999.1 2021-07-16
EP21305999 2021-07-16
PCT/EP2022/069472 WO2023285466A1 (en) 2021-07-16 2022-07-12 Imidazo[1,2-b][1,2,4]triazol derivatives for use in therapy

Publications (2)

Publication Number Publication Date
JP2024525791A true JP2024525791A (ja) 2024-07-12
JP2024525791A5 JP2024525791A5 (https=) 2025-07-22

Family

ID=77126712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502013A Pending JP2024525791A (ja) 2021-07-16 2022-07-12 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体

Country Status (7)

Country Link
US (1) US20240300956A1 (https=)
EP (1) EP4370518A1 (https=)
JP (1) JP2024525791A (https=)
CN (1) CN117916240A (https=)
AR (1) AR126471A1 (https=)
TW (1) TW202321245A (https=)
WO (1) WO2023285466A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3581380B2 (ja) * 1993-08-17 2004-10-27 富士写真フイルム株式会社 アゾメチン色素およびそれを含有する熱転写色素供与材料
US20040010056A1 (en) * 2002-06-28 2004-01-15 Konica Corporation Colored particle dispersion, ink jet ink, dye, and ink jet recording method
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
EP4370516A1 (en) * 2021-07-16 2024-05-22 Sanofi 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy

Also Published As

Publication number Publication date
US20240300956A1 (en) 2024-09-12
EP4370518A1 (en) 2024-05-22
TW202321245A (zh) 2023-06-01
WO2023285466A1 (en) 2023-01-19
CN117916240A (zh) 2024-04-19
AR126471A1 (es) 2023-10-11

Similar Documents

Publication Publication Date Title
JP7039802B2 (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
US10988456B2 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
KR20210135561A (ko) 피라진 유도체 및 shp2 억제에서의 그의 적용
CN115215847A (zh) 一类kras-sos1抑制剂、其制备方法及其应用
WO2023280182A1 (zh) 作为kat6抑制剂的化合物
HUE029275T2 (en) Phthalazinone ketone derivative, method of preparation and therapeutic use
JP2016519674A (ja) 過剰増殖障害を治療または予防するための３−アセチルアミノ−１−（フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ）ベンゼン誘導体
AU2015336458B2 (en) KCNQ2-5 channel activator
WO1998018765A1 (fr) Composes de 1-phenylpyrazole et leur application pharmaceutique
WO2004106325A1 (en) Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
CN114269720A (zh) 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
CA3068083A1 (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
JP2017511309A (ja) Ｗｎｔシグナル伝達経路の阻害剤
JP2024525792A (ja) 治療に使用するための６Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］ピリジン誘導体
KR20200123184A (ko) 증식이상 장애를 치료하기 위한 물질 및 방법
EP4644386A1 (en) Novel compound, and pharmaceutical composition for prevention or treatment of cancer or tumors comprising same
JP2024525791A (ja) 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体
EP4240738B1 (en) Pyrazole derivatives as ret kinase inhibitors
JP2018505906A (ja) Ｗｎｔシグナル伝達経路の阻害剤としての１，３，４−チアジアゾール−２−イル−ベンズアミド誘導体
JP2018507212A (ja) Ｎ−フェニル−（モルホリン−４−イルまたはピペラジニル）アセトアミド誘導体およびｗｎｔシグナル伝達経路の阻害剤としてのその使用
WO2023116763A1 (zh) 一种哒嗪类化合物、其药物组合物及应用
WO2022161263A1 (zh) 新型Hedgehog信号通路抑制剂
AU2023366352A1 (en) New inhibitors of phosphatidylinositol 3-kinase
KR20260022307A (ko) Trek(twik 관련 k+ 채널) 채널 기능의 억제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250711